ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
How ICON is Using Analytics & Wearables to Enhance Clinical Trials
The company is investing in emergent technology to boost the attractiveness of trials as a care option and attract more participants.
21st Century Cures Act: Ushering in a New Chapter in the Expanding Use of Real-World Evidence
A recent ICON article published by PharmaFocus on the 21st Century Cures Act and the relative expanding use of real-world evidence (RWE).
Patients is a Virtue
An article on patient service solutions, featuring commentary from Matt McCarty, Kelly Franchetti and Gretchen Goller
Next Generation of Clinical Trials
In this edition of PharmaTimes, ICON's Tom O’Leary comments on the next generation of trials in particular participant engagement, expansive data & digital tech
Wearables in Virtual Trials
Connected health including wearable devices and mobile health (mHealth) technology, is providing an opportunity for patient-centric data.
Navigating the Labyrinth of Regulation and Taking Drug Safety Reporting to the Next Level with Automation
An article on the challenges of global clinical trials in an ever- changing regulatory environment, and more.
Special Report on Immunology & Autoimmunity: Turn of the coin
A Drug Discovery News (DDN) article featuring commentary from ICON expert Marco Silleni, discussing the challenges of autoimmune disorders.
Immunotherapy Combination Trials Q&A
A Q&A article discussing how best to achieve success in an increasingly crowded, competitive immuno-oncology field.
ICON Introduces New Drug Safety Reporting Solution
An Outsourcing Pharma article featuring commentary from Quintin Van Wyk on ICON’s new drug safety reporting platform.
Adopting a Strategy to Identify Highest Commercial Value Products
A thought leadership article written by Vicki Anastasi and published by JMDR exploring the challenges of transitioning to the new EU MDR and IVDR.